

August 09, 2024

To

The Chief General Manager
Listing Operation,
BSE Limited,
20th Floor, P. J. Towers,
Dalal Street, Mumbai – 400 001.

Scrip Code: 524743

Dear Sir / Madam,

Sub: Intimation about the Board Meeting for the quarter ended 30th June 2024.

Ref: Regulation 29 of SEBI (LODR) Regulations 2015 as amended

Pursuant to Regulation 29 of the Securities and exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, the 14th August 2024, through video conferencing, inter alia, to consider the following:

1. To take on record the unaudited Standalone and Consolidated financial results of the Company for the quarter ended 30th June 2024
2. The proposal for fund raising by way of preferential issue / private placement of securities for cash / other than cash, including determination of Issue Price subject to such regulatory/statutory approvals as may be required, including the approval of shareholders of the Company.
3. To transact other incidental and ancillary matters as may be decided by the board.

This is for your information and records.

As informed earlier vide our letter dated 27th June 2024, the trading window for dealing in the equity shares of the Company is already closed for all designated persons, their immediate relatives, other connected persons and shall remain closed till the conclusion of 48 hours after the declaration of financial results of the Company for the quarter ended 30th June 2024.

Thanking You,

Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**

(Formerly known as Fischer Chemic Limited)



RAVINDRAN GOVINDAN

CHAIRMAN & MANAGING DIRECTOR